Singular Genomics Announces 1-for-30 Reverse Stock Split
2024年6月22日 - 5:05AM
Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company
leveraging novel next-generation sequencing (NGS) and spatial
multiomics technologies to empower researchers and clinicians,
today announced that on June 26, 2024, effective at 12:01 a.m.
Eastern Time, it will effectuate a 1-for-30 reverse split of its
common stock. The Company’s common stock will begin trading on a
split-adjusted basis when the market opens on June 26, 2024 under
its current trading symbol “OMIC”. The CUSIP number of the
Company’s common stock following the reverse stock split will be
82933R 308.
The reverse stock split is intended to enable the Company to
regain compliance with the minimum bid price requirement for
continued listing on The Nasdaq Capital Market. The reverse stock
split was approved by the Company’s stockholders at the Annual
Meeting of Stockholders held on May 29, 2024, with the final ratio
determined by the Company’s Board of Directors.
The Company plans to file an amendment to its certificate of
incorporation with the Secretary of State of Delaware on or around
June 25, 2024. The reverse stock split will not reduce the number
of authorized shares of the Company’s common stock, which will
remain at 400,000,000, and will not change the par value of its
common stock, which will remain at $0.0001 per share.
The 1-for-30 reverse stock split will automatically convert 30
shares of the Company’s common stock into one new share of common
stock. No fractional shares will be issued in connection with the
reverse stock split. Holders of common stock otherwise entitled to
a fractional share because of the reverse stock split will
automatically be entitled to receive an additional fraction of a
share of common stock to round up to the next whole share. The
reverse stock split will reduce the number of shares of outstanding
common stock from approximately 74.7 million shares to
approximately 2.5 million shares. The reverse stock split will not
reduce the number of shares of the Company’s Series A Preferred
Stock outstanding, which will remain at 2,500 shares but will be
subject to a proportional conversion ratio adjustment.
Additionally, outstanding equity-based awards and other outstanding
equity rights will be proportionately adjusted.
The Company’s transfer agent, Continental Stock Transfer &
Trust Company, will act as the exchange agent for the reverse stock
split. Stockholders of record will receive information from
Continental regarding their stock ownership following the reverse
stock split. Stockholders owning shares via a bank, broker or other
nominee will have their positions automatically adjusted to reflect
the reverse stock split and will not be required to take further
action in connection with the reverse stock split, with such
adjustment subject to each bank, broker or other nominee’s
particular processes. Continental can be reached at (212) 509-4000
to answer any questions.
Additional information concerning the reverse stock split can be
found in the Company’s definitive proxy statement on Schedule 14A
filed with the SEC on April 18, 2024 and in the Company’s current
report on Form 8-K filed with the SEC on May 30, 2024.
About Singular Genomics Systems, Inc.Singular
Genomics is a life science technology company that develops
next-generation sequencing and multiomics technologies. The
commercially available G4® Sequencing Platform is a powerful,
highly versatile benchtop genomic sequencer designed to produce
fast and accurate results. In addition, the company is currently
developing the G4X™ Spatial Sequencer, which will leverage
Singular’s proprietary sequencing technology, applying it as an in
situ readout for transcriptomics, proteomics and fluorescent
H&E in tissue, with spatial context and on the same platform as
the G4. Singular Genomics’ mission is to empower researchers and
clinicians to advance science and medicine. Visit
www.singulargenomics.com for more information.
Forward-looking StatementsCertain statements
contained in this press release, other than historical information,
constitute forward-looking statements within the meaning of the
federal securities laws. Forward-looking statements include, but
are not limited to, statements concerning expectations regarding
the completion and the effect of the reverse stock split including
its impact on the Company’s stock price and continued listing on
the Nasdaq Capital Market. In some cases, forward-looking
statements can be identified by terms such as “anticipates,”
“believes,” “could,” “estimates,” “expects,” “foresees,”
“forecasts,” “guidance,” “intends” “goals,” “may,” “might,”
“outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,”
“should,” “targets,” “will,” “would” or similar expressions and the
negatives of those terms. These forward-looking statements are
subject to risks, uncertainties, and assumptions. If the risks
materialize or assumptions prove incorrect, actual results could
differ materially from the results implied by these forward-looking
statements. New risks emerge from time to time. It is not possible
for our management to predict all risks, nor can we assess the
impact of all factors on our business or the extent to which any
factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements we may make. Further information on these and additional
risks that could affect Singular Genomics’ results is included in
its filings with the Securities and Exchange Commission (SEC),
including its most recent Annual Report on Form 10-K and Quarterly
Report on Form 10-Q, and future reports that Singular Genomics may
file with the SEC from time to time, which could cause actual
results to vary from expectations. Any forward-looking statement
made by Singular Genomics in this press release speaks only as of
the day on which Singular Genomics makes it. Singular Genomics
assumes no obligation to, and does not currently intend to, update
any such forward-looking statements after the date of this
release.
Investor ContactPhilip Trip TaylorGilmartin
Groupir@singulargenomics.com
Media ContactMatt
Browningpr@singulargenomics.com
Singular Genomics Systems (NASDAQ:OMIC)
過去 株価チャート
から 5 2024 まで 6 2024
Singular Genomics Systems (NASDAQ:OMIC)
過去 株価チャート
から 6 2023 まで 6 2024